Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study)
International Journal of Colorectal Disease · 23.04.2026 · 41 (1)
DOI: 10.1007/s00384-026-05112-y ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Colorectal Disease, online erschienen am 23.04.2026. Verfasst von Xavier Serra-Aracil und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Universitat Autònoma de Barcelona, Coloproctology Unit, Parc Tauli University Hospital, Institut d'investigació I Innovació Pa…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Chemoradiotherapy, Transanal Endoscopic Surgery. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Universitat Autònoma de Barcelona.
Abstract (Originalsprache)
Purpose
For clinical (c) T1N0M0 rectal adenocarcinoma without adverse pathological features, local excision by transanal endoscopic surgery (TEM) is standard; however, contemporary series still report local recurrence (LR) rates of 15–20%. Preoperative unfavorable histopathologic features cannot reliably identify high-risk pT1 disease, and both completion total mesorectal excision (TME) and salvage TME for LR carry relevant morbidity and functional impairment. Building on our prior phase III trial in T2–T3abN0M0 (TAUTEM study), showing that preoperative chemoradiotherapy (CRT) followed by TEM achieved a 7.4% LR with improved postoperative outcomes, we hypothesize that CRT + TEM will increase rectal preservation in cT1N0M0 without compromising oncologic safety or quality of life. The TAUTEM-T1 trial tests this hypothesis.
Methods
Multicenter, prospective, randomized, controlled, phase III superiority trial. Adults with biopsy-proven rectal low or moderate grade adenocarcinoma ≤ 4 cm, located < 10 cm from the anal verge, staged as cT1N0M0, are randomized (1:1) to: CRT (long-course radiotherapy with concurrent capecitabine) followed by TEM at week 10, or TEM alone. The primary endpoint is rectal preservation at 3 years. Secondary endpoints include postoperative morbidity/mortality, CRT-related adverse events, quality of life and anorectal function, and long-term oncologic outcomes (local/distant recurrence, overall and disease-free survival). Planned sample size: 106 patients.
Results
This manuscript describes the rationale and design of the TAUTEM-T1 randomized trial.
Conclusion
TAUTEM-T1 will assess whether preoperative CRT followed by TEM increases rectal preservation in cT1N0M0 rectal cancer without compromising oncologic safety, quality of life, or bowel function.
Trial registration
ClinicalTrials.gov, NCT06450574.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Universitat Autònoma de Barcelona, Coloproctology Unit, Parc Tauli University Hospital, Institut d'investigació I Innovació Parc Tauli I3PT-CERCA, Sabadell (Barcelona), Spain. javier.serra@uab.cat.
- Department of Surgery, Universitat Autònoma de Barcelona, Coloproctology Unit, Parc Tauli University Hospital, Institut d'investigació I Innovació Parc Tauli I3PT-CERCA, Sabadell (Barcelona), Spain.
- Department of Pathology, Universitat Autònoma de Barcelona, Parc Tauli University Hospital, Institut d'investigació I Innovació Parc Tauli I3PT-CERCA, Sabadell (Barcelona), Spain.
- Medical Oncology Department, Mutua de Terrassa University Hospital, Terrassa (Barcelona), Spain.
- Colorectal Unit, General and Digestive Surgery Department, Bellvitge University Hospital, Barcelona, Spain.
- Colorectal Unit, General and Digestive Surgery Department, Vall d'Hebron University Hospital, Departamento de Cirugía, Universitat Autònoma de Barcelona, Barcelona, Spain.
Förderung
- Instituto de Salud Carlos III
- Universitat Autònoma de Barcelona
Zitieren
APA
Serra-Aracil, X., Nonell, A., Gener-Jorge, C., Pericay, C., Golda, T., Kreisler, E., Espin-Basany, E., Pallisera, A., Badia-Closa, J., Espina, B., Borda-Arrizabalaga, N., Reina, A., Guadalajara-Labajo, H., Otero, A., Delgado, S., Kraft, M., Querol, R., Flor, B., Pellino, G., …, & TAUTEM-T1 collaborative group (2026). Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study). International Journal of Colorectal Disease, 41(1). https://doi.org/10.1007/s00384-026-05112-y
Vancouver
Serra-Aracil X, Nonell A, Gener-Jorge C, Pericay C, Golda T, Kreisler E, et al. Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study). International Journal of Colorectal Disease. 2026;41(1). doi:10.1007/s00384-026-05112-y
BibTeX
@article{SerraAracil2026,
author = {Serra-Aracil, Xavier and Nonell, Anna and Gener-Jorge, Cristina and Pericay, Carles and Golda, Thomas and Kreisler, Esther and Espin-Basany, Eloy and Pallisera, Anna and Badia-Closa, Jesus and Espina, Beatriz and Borda-Arrizabalaga, Nerea and Reina, Angel and Guadalajara-Labajo, Hector and Otero, Ana and Delgado, Salvadora and Kraft, Miquel and Querol, Rosa and Flor, Blas and Pellino, Gianluca and Biondo, Sebastiano and Caro-Tarrago, Aleidis and TAUTEM-T1 collaborative group, TAUTEM-T1 collaborative group},
title = {Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study)},
journal = {International Journal of Colorectal Disease},
year = {2026},
volume = {41},
number = {1},
doi = {10.1007/s00384-026-05112-y}
}
EUVIMED